Defining ETS transcription regulatory networks and their contribution to breast cancer progression

Journal of Cellular Biochemistry

Volumn 102, Issue 3, 2007, Pages 549-559

  Turner, David P ^a,b   Findlay, Victoria J ^a,b   Moussa, Omar ^a,b   Watson, Dennis K ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Breast cancer; ETS; Microenvironment; Proteome; Transcriptional regulation

Indexed keywords

PROTEOME; RNA; TRANSCRIPTION FACTOR ETS;

ACCURACY; BREAST CANCER; CANCER GROWTH; CELL INTERACTION; GENE CONTROL; GENE FUNCTION; HOMEOSTASIS; HUMAN; METASTASIS; MULTIGENE FAMILY; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; REVIEW; STROMA CELL; TUMOR CELLS AND CELL LINES;

ANIMALS; BREAST NEOPLASMS; CELLS, CULTURED; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; MODELS, GENETIC; NEOPLASM METASTASIS; NEOPLASMS; PHENOTYPE; PROTEOMICS; PROTO-ONCOGENE PROTEIN C-ETS-1; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 35048859402     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21494     Document Type: Review

References (52)

1. Aggarwal K, Choe LH, Lee KH. 2006. Shotgun proteomics using the iTRAQ isobaric tags. Brief Funct Genomic Proteomic 5:112-120.
2. Benz CC, O'Hagan RC, Richter B, Scott GK, Chang CH, Xiong X, Chew K, Ljung BM, Edgerton S, Thor A, Hassell JA. 1997. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 15:1513-1525.
3. Bertucci F, Birnbaum D, Goncalves A. 2006. Proteomics of breast cancer: Principles and potential clinical applications. Mol Cell Proteomics 5:1772-1786.
4. Bissell MJ, Kenny PA, Radisky DC. 2005. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: The role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol 70:343-356.
5. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. 2005. PARI is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120:303-313.
6. Bosc DG, Goueli BS, Janknecht R. 2001. HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene 20:6215-6224.
7. Brand M, Ranish JA, Kummer NT, Hamilton J, Igarashi K, Francastel C, Chi TH, Crabtree GR, Aebersold R, Groudine M. 2004. Dynamic changes in transcription factor complexes during erythroid differentiation revealed by quantitative proteomics. Nat Struct Mol Biol 11:73-80.
8. Buggy Y, Maguire TM, McGreal G, McDermott E, Hill AD, O'Higgins N, Duffy MJ. 2004. Overexpression of the Ets-1 transcription factor in human breast cancer. Br J Cancer 91:1308-1315.
9. Buggy Y, Maguire TM, McDermott E, Hill AD, O'Higgins N, Duffy MJ. 2006. Ets2 transcription factor in normal and neoplastic human breast tissue. Eur J Cancer 42:485-491.
10. Davidoff AM, Kerns BJ, Pence JC, Marks JR, Iglehart JD. 1991. p53 alterations in all stages of breast cancer. J Surg Oncol 48:260-267.
11. Debies MT, Welch DR. 2001. Genetic basis of human breast cancer metastasis. J Mammary Gland Biol Neoplasia 6:441-451.
12. Dillon RL, White DE, Muller WJ. 2007. The phosphatidyl inositol 3-kinase signaling network: Implications for human breast cancer. Oncogene 26:1338-1345.
13. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL. 2006. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25:3994-4008.
14. Dressman HK, Hans C, Bild A, Olson JA, Rosen E, Marcom PK, Liotcheva VB, Jones EL, Vujaskovic Z, Marks J, Dewhirst MW, West M, Nevins JR, Blackwell K. 2006. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 12:819-826.
15. Duffy MJ. 2002. Urokinase-type plasminogen activator: A potent marker of metastatic potential in human cancers. Biochem Soc Trans 30:207-210.
16. Escot C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest J, Callahan R. 1986. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA 83:4834-4838.
17. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM. 2006. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560-569.
18. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK. 2003. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 63:4626-4631.
19. Fournier MV, Martin KJ, Kenny PA, Xhaja K, Bosch I, Yaswen P, Bissell MJ. 2006. Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res 66:7095-7102.
20. Fung YK, T'Ang A. 1992. The role of the retinoblastoma gene in breast cancer development. Cancer Treat Res 61:59-68.
21. Galang CK, Muller WJ, Foos G, Oshima RG, Hauser CA. 2004. Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J Biol Chem 279:11281-11292.
22. Ghadersohi A, Pan D, Fayazi Z, Hicks DG, Winston JS, Li F. 2007. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat 102:19-30.
23. Hollenhorst PC, Jones DA, Graves BJ. 2004. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res 32:5693-5702.
24. Hsu T, Trojanowska M, Watson DK. 2004. Ets proteins in biological control and cancer. J Cell Biochem 91:896-903.
25. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JE, Liu ET, Bergh J, Kuznetsov VA, Miller LD. 2006. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66:10292-10301.
26. Jackers P, Szalai G, Moussa O, Watson DK. 2004. Ets-dependent regulation of target gene expression during megakaryopoiesis. J Biol Chem 279:52183-52190.
27. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 2007. Cancer statistics, 2007. CA Cancer J Clin 57:43-66.
28. Lee GY, Kenny PA, Lee EH, Bissell MJ. 2007. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4:359-365.
29. Loi S, Piccart M, Sotiriou C. 2007. The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. Crit Rev Oncol Hematol 61:187-194.
30. Luo Y, Cai J, Xue H, Miura T, Rao MS. 2005. Functional SDF1 alpha/CXCR4 signaling in the developing spinal cord. J Neurochem 93:452-462.
31. Ma Y, Qian Y, Wei L, Abraham J, Shi X, Castranova V, Harner EJ, Flynn DC, Guo L. 2007. Population-based molecular prognosis of breast cancer by transcriptional profiling. Clin Cancer Res 13:2014-2022.
32. Manavathi B, Rayala SK, Kumar R. 2007. Phosphorylation-dependent regulation of stability and transforming potential of ETS transcriptional factor ESE-1 by p21-activated kinase 1. J Biol Chem 282:19820-19830.
33. Maroni P, Bendinelli P, Matteucci E, Desiderio MA. 2007. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB. Carcinogenesis 28:267-279.
34. Nielsen BS, Rank F, Illemann M, Lund LR, Dano K. 2007. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int J Cancer 120: 2086-2095.
35. O'Brien LE, Zegers MM, Mostov KE. 2002. Opinion: Building epithelial architecture: Insights from three-dimensional culture models. Nat Rev Mol Cell Biol 3:531-537.
36. Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ. 1992. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 89:9064-9068.
37. Ranish JA, Yi EC, Leslie DM, Purvine SO, Goodlett DR, Eng J, Aebersold R. 2003. The study of macromolecular complexes by quantitative proteomics. Nat Genet 33:349-355.
38. Rochlitz CF, Scott GK, Dodson JM, Liu E, Dollbaum C, Smith HS, Benz CC. 1989. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res 49:357-360.
39. Salh B, Marotta A, Wagey R, Sayed M, Pelech S. 2002. Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer. Int J Cancer 98:148-154.
40. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, Fehm T, Solomayer E, Riess O, Wallwiener D, Kurek R, Neubauer HJ. 2006. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 66:5278-5286.
41. Sementchenko VI, Watson DK. 2000. Ets target genes: Past, present and future. Oncogene 19:6533-6548.
42. Seth A, Watson DK. 2005. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41:2462-2478.
43. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A., et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712.
44. Toole BP. 2003. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol 54:371-389.
45. Tugores A, Le J, Sorokina I, Snijders AJ, Duyao M, Reddy PS, Carlee L, Ronshaugen M, Mushegian A, Watanaskul T, Chu S, Buckler A, Emtage S, McCormick MK. 2001. The epithelium-specific ETS protein EHF/ESE-3 is a context-dependent transcriptional repressor downstream of MAPK signaling cascades. J Biol Chem 276:20397-20406.
46. Turner DP, Moussa O, Sauane M, Fisher PB, Watson DK. 2007. Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res 67:1618-1625.
47. van Kempen LC, de Visser KE, Coussens LM. 2006. Inflammation, proteases and cancer. Eur J Cancer 42:728-734.
48. Wang F, Hansen RK, Radisky D, Yoneda T, Barcellos-Hoff MH, Petersen OW, Turley EA, Bissell MJ. 2002. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst 94:1494-1503.
49. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J. 2004. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64:7022-7029.
50. Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137.
51. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, Oettgen P. 2005. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest 115:2508-2516.
52. Zhou J, Ng AY, Tymms MJ, Jermiin LS, Seth AK, Thomas RS, Kola I. 1998. A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13-15, a region subject to LOH and rearrangement in human carcinoma cell lines. Oncogene 17:2719-2732.